The UK based drug firm GSK has agreed to pay up to $2.2bn (£1.7bn; €2bn) to settle claims that the heartburn drug ranitidine (previously marketed in the US as Zantac) caused cancer. The deal, ...
GSK has faced a long-running saga around Zantac, which is the brand name for the drug ranitidine. The product reduces the amount of acid the stomach makes, and was a best-seller in the UK and US ...